BD closes TVA Medical buy

Becton Dickinson (NYSE:BDX) wasted no time in closing the cash buyout of  TVA Medical, which just a few weeks ago landed FDA clearance for its EverlinQ EndoAVF hemodialysis device, for an undisclosed amount. Austin, Texas-based TVA won de novo clearance June 22 for the EverlinQ EndoAVF device, which uses a pair of magnetic catheters and radiofrequency energy to create an arteriovenous fistula for hemodialysis access without open surgery. BD said today that it plans to change the system’s name to WavelinQ EndoAVF as it integrates TVA into its peripheral intervention business. “The FDA’s authorization and joining BD are the culmination of many years of hard work by a dedicated team of innovators at TVA Medical and I’d like to thank them for their tireless efforts to get us to these important milestones,” co-founder Adam Berman said in prepared remarks. “BD will enable us to deliver to physicians and patients what we believe is a highly desirable and transformative endovascular technology as an integral part of a broader [end-stage renal disease]-focused portfolio of solutions. I look forward to the next chapter of our history as part of the BD family.” “The addition of TVA Medical allows BD to provide another innovative device to physicians who treat patients suffering from chronic kidney disease requiring hemodialysis,” added peripheral intervention president Steve Williamson. “This technology is h...
Source: Mass Device - Category: Medical Devices Authors: Tags: Dialysis Mergers & Acquisitions bectondickinson TVA Medical Source Type: news

Related Links:

Conclusions: Higher MCV was associated with higher all-cause, cardiovascular, and infectious mortality in HD patients. Further investigation is necessary to understand the underlying nature of the observed association.Nephron
Source: Nephron - Category: Urology & Nephrology Source Type: research
This study assessed treatment routine, effective...
Source: BMC Nephrology - Category: Urology & Nephrology Authors: Tags: Research article Source Type: research
Abstract Dysgeusia (abnormal taste) is common in those with chronic kidney disease and contributes to poor nutritional intake. Previous sensory work has shown that taste improves after dialysis sessions. The goal of this pilot study was to characterize altered taste perceptions in patients on dialysis compared to healthy adults, and to evaluate relationships between serum parameters with taste perceptions. We hypothesized that patients undergoing dialysis would experience blunted taste intensities compared to controls, and that serum levels of potential tastants would be inversely related to taste perception of co...
Source: Chemical Senses - Category: Biochemistry Authors: Tags: Chem Senses Source Type: research
Purpose of review To identify recent data that inform the management of individuals with HIV and chronic kidney disease. Recent findings Several nonnucleoside reverse transcriptase, protease, and integrase strand transfer inhibitors inhibit tubular creatinine secretion resulting in stable reductions in creatinine clearance of 5–20 ml/min in the absence of other manifestations of kidney injury. Progressive renal tubular dysfunction is observed with tenofovir disoproxil fumarate in clinical trials, and more rapid decline in estimated glomerular filtration rate in cohort studies of tenofovir disoproxil fumarate a...
Source: Current Opinion in Infectious Diseases - Category: Infectious Diseases Tags: HIV INFECTIONS AND AIDS: Edited by David Dockrell Source Type: research
Abstract In both women and men, chronic kidney disease (CKD) is associated with decreased fertility. Though a multitude of factors contribute to the reduction in fertility in this population, progressively impaired function of the hypothalamic-pituitary-gonadal axis appears to play a key role in the pathophysiology. There is limited research on strategies to manage infertility in the CKD population, but intensive hemodialysis, kidney transplantation, medication management and assisted reproductive technologies (ART) have all been proposed. Though fertility and reproductive care are reported as important elements o...
Source: Journal of Nephrology - Category: Urology & Nephrology Authors: Tags: J Nephrol Source Type: research
In the original publication, age stratified mortality rates were incorrectly added in Fig. 2. The correct Fig. 2 is given below.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
Abstract Chronic hepatitis C (CHC) is the most common cause of infection related deaths in USA according to Central Disease Control and Prevention (CDC) report in 2016. Hepatitis C is a blood borne virus and is common in chronic kidney disease (CKD) and in hemodialysis (HD) dependent patients. A majority of patients with CHC could remain asymptomatic and are still undiagnosed. Early detection of CHC and linkage of infected patients to care for evaluation and treatment is the standard of care as emphasized by Kidney Disease Improving Global Outcome (KDIGO) and American Association for the Study of Liver Disease- In...
Source: Seminars in Dialysis - Category: Urology & Nephrology Authors: Tags: Semin Dial Source Type: research
CONCLUSIONS: The results suggest that it may be difficult to increase muscle mass with strength training in patients who are undergoing haemodialysis. Muscle growth may be impaired as a result of several catabolic conditions. Strength training was associated with important clinical outcomes including increased muscle strength and improved self-rated physical health and function. PMID: 30573007 [PubMed - in process]
Source: Danish Medical Journal - Category: General Medicine Tags: Dan Med J Source Type: research
ConclusionRIPC does not result in significant reduction of CIN. However RIPC helps in the prevention of post procedural worsening in eGFR and serum creatinine even up to 6 weeks.
Source: Indian Heart Journal - Category: Cardiology Source Type: research
A daily single-tablet regimen of coformulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide, approved in the U.S. and elsewhere for HIV-1-infected patients with mild-to-moderate chronic kidney disease, may also work well in those with end-stage renal disease on chronic hemodialysis, a new study suggests.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news
More News: Chronic Kidney Disease | Dialysis | Hemodialysis | Mergers and Aquisitions | Urology & Nephrology